Down-staging prostate cancer. Is it possible by androgen depletion and Mitomycin C therapy?
The study was carried out in order to investigate the possibility of tumor reduction in prostate cancer patients. As a reduction of the primary tumor was observed with hormonal treatment and complete response of soft tissue tumor markers with Mitomycin C, this combined treatment was given in seven patients to evaluate if it was able to down-stage those cases which were thought to be incurable (T3N1-2M0/T4N0-2M0). Although the clinical evaluation suggested a significant down-staging, the explorative lymphadenectomy was unable to confirm this. The proposed treatment is able to reduce the tumor bulk significantly of the primary cancer as well as of its metastases; progression during the treatment was not seen.
Verbaeys
A
A
Department of Urology, University Hospital Gent, Belgium.
Carpentier
P
P
Cuvelier
C
C
Praet
M
M
Fonteyne
E
E
Morelle
V
V
De Sy
W A
WA
D000368:Aged; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D017273:Goserelin / Q000008:administration & dosage*; D006801:Humans; D008197:Lymph Node Excision; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage*; D009367:Neoplasm Staging; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology*
D017273:Goserelin; D016685:Mitomycin